Non High-Density Lipoprotein Cholesterol in Type2 Diabetic Patients
Published: 2021-05-07
Page: 57-62
Issue: 2021 - Volume 4 [Issue 1]
Mouna Elleuch
Department of Endocrinology Diabetology, Hedi Chaker Hospital, Sfax University, Tunisia.
Hana Charfi
*
Department of Endocrinology Diabetology, Hedi Chaker Hospital, Sfax University, Tunisia.
Sahar Mekki
Department of Endocrinology Diabetology, Hedi Chaker Hospital, Sfax University, Tunisia.
Dhoha Ben Salah
Department of Endocrinology Diabetology, Hedi Chaker Hospital, Sfax University, Tunisia.
Wajdi Sefi
Department of Endocrinology Diabetology, Hedi Chaker Hospital, Sfax University, Tunisia.
Kaouthar El Arbi
Department of Endocrinology Diabetology, Hedi Chaker Hospital, Sfax University, Tunisia.
Khouloud Boujelbene
Department of Endocrinology Diabetology, Hedi Chaker Hospital, Sfax University, Tunisia.
Nedia Charfi
Department of Endocrinology Diabetology, Hedi Chaker Hospital, Sfax University, Tunisia.
Fatma Mnif
Department of Endocrinology Diabetology, Hedi Chaker Hospital, Sfax University, Tunisia.
Mouna Mnif
Department of Endocrinology Diabetology, Hedi Chaker Hospital, Sfax University, Tunisia.
Faten Hadj Kacem
Department of Endocrinology Diabetology, Hedi Chaker Hospital, Sfax University, Tunisia.
Mohamed Abid
Department of Endocrinology Diabetology, Hedi Chaker Hospital, Sfax University, Tunisia.
*Author to whom correspondence should be addressed.
Abstract
Aims: To study the relationship between non high-density lipoprotein cholesterol (non-HDL-C) and metabolic disorders in type2 diabetic patients and to prove the incrimination of non-HDL-C in the genesis of chronic complications of diabetes.
Study Design: Retrospective study.
Place and Duration of Study: Endocrinology-Diabetology Department of Hedi Chaker University Hospital of Sfax for a period of two months, January and February 2020.
Methodology: We included80 type2 diabetic patients (34 men and 46 women; age range: 22-72 years) with metabolic syndrome. Each patient had undergone a complete clinical examination and biochemistry test, then, the non-HDL-C was calculated.
Results: Out of 80 patients, 57 suffered from diabetic complications like micro vascular and macro vascular complications. Unbalanced diabetes was identified in 73.75% of the patients. All the patients had a high level of non-HDL-C.
No significant positive correlation was confirmed between non-HDL-C with body mass index, glycemic parameters, triglycerides, or total cholesterol.
Correlation between the level of non-HDL-C and coronary artery disease, myocardial infarction (MI), and stroke was identified with p values of 0.016, 0.05, and 0.04, respectively.
Patients with microvascular complications had higher levels of non-HDL-C but a positive correlation was only relevant with diabetic nephropathy (p=0.026).
Conclusion: Our study confirmed that non-HDL-C is a simple and reliable indicator of the overall risk of cardiovascular disease, thus, it may be equivalent, if not superior, to low-density lipoprotein cholesterol (LDL-C). Therefore, it should be our primary lipid treatment target for diabetic patients.
Keywords: Non-high-density lipoprotein cholesterol, diabetes, diabetic complications, metabolic syndrome